Active, not recruitingPHASE2, PHASE3NCT05686356

A Pan-TB Regimen Targeting Host and Microbe

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Aurum Institute NPC
Principal Investigator
Professor Robert Wallis, MD
The Aurum Institute NPC
Intervention
Sutezolid(drug)
Enrollment
352 enrolled
Eligibility
18-65 years · All sexes
Timeline
20232026

Study locations (8)

Collaborators

Ludwig-Maximilians - University of Munich · Stichting Katholieke Universiteit · Wits Health Consortium (Pty) Ltd · Instituto Nacional de Saúde, Mozambique · National Institute for Medical Research, Tanzania · University of Stellenbosch · Sequella, Inc. · Global Alliance for TB Drug Development

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05686356 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials